Skip to Content

GeneDx Holdings Corp

Securities Class Action

  • Date:
  • 5/9/2026
  • Company Name:
  • GeneDx Holdings Corp
  • Stock Symbol:
  • WGS
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) on behalf of GeneDx stockholders. Our investigation concerns whether GeneDx has violated the federal securities laws and/or engaged in other unlawful business practices.

On May 4, 2026, GeneDx released its first quarter 2026 financial results, revealing earnings per share of -$0.28, and a $57.5 million loss from operations. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint. GeneDx revealed it had "lower-than-expected blended average reimbursement rate for exome and genome" and "softer-than-expected performance from [its] noncore business lines" including Fabric Genomics. The Company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit, "primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations." On this news, the price of GeneDx shares declined by $33.42 per share, or approximately 50%, from $67.93 per share on May 4, 2026 to close at $34.51 on May 5, 2026.
 
If you purchased or otherwise acquired GeneDx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions about the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in GeneDx Holdings Corp. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: